4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine

(AIM: 4BB), a specialist in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, announces an expansion of its DNA offering to support the production of critical starting material for personalised mRNA medicines.

The expanded offering across 4basebio’s high quality (HQ) and current Good Manufacturing Practice (cGMP) operations in Cambridge enables shortened manufacturing turnaround times and small patient-specific batch sizes and rapid batch release. These innovations support faster and more reliable delivery of the high-purity synthetic DNA, which is increasingly needed to meet demand for next-generation personalised mRNA medicines and individualised treatment programmes. Enhanced process controls and quality systems ensure the integrity required for these medicines.

Scott Lorimer, Chief Operating Officer, 4basebio:

“Personalised medicine places a very different set of demands on manufacturing than traditional biologics, including shorter turnaround times, smaller batch sizes, and zero tolerance for variability between batches. We've expanded and upgraded our HQ and cGMP operations to meet those demands: additional suite capacity, tightened process control, and quality systems built around rapid batch release.”

Amy Walker, Chief Executive Officer, 4basebio:

“The growing demand for personalised medicines such as cancer vaccines requires a new paradigm for DNA manufacturing, particularly around the production of small batches of product. Traditional plasmid DNA, which is routinely used for DNA manufacturing, was never designed for the production of small batches that are needed for personalised medicine, and carries time delays, extended costs and contamination risks.

“Synthetic DNA removes those constraints entirely. Our cell-free platform gives developers a high-purity template, produced on a timeline measured in weeks rather than months, that is built for the realities of personalised treatment. This expansion of our capacity is about making sure we can deliver that same speed and quality at HQ and GMP scale, so that no patient's treatment is delayed waiting on their DNA.”

Last month Moderna Inc. and Merck & Co. announced that their personalised mRNA cancer vaccine, intismeran autogene, succeeded in a landmark Phase 3 trial for high-risk melanoma, the first positive Phase 3 trial for an individualised mRNA cancer vaccine.

The global personalised cancer vaccine market was valued at approximately US$200 million in 2024 and is projected to increase to $1.4 billion by 2030, representing a CAGR of 45%

1

.

4basebio’s manufacturing technology enables integrated, flexible production of DNA at the company’s Cambridge, UK sites with custom built cleanrooms for HQ and cGMP operations, in addition to Research Use Only (RUO) production facilities for pre-clinical development work.

References

Grand View Research – Personalized Cancer Vaccine Market (2025 - 2030)

.

4392470_0.png